



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent: Anti-HIV-1 gp120 Monoclonal (F105)

Catalog Number: 857

Lot Number: 150350

Release Category: C

Provided: 100 µg of purified antibody at 1.5 mg/ml, dialyzed into PBS and sterile filtered.

Description: F105 binds to a discontinuous, or conformational, gp120 epitope.

Host: Human EBV-transformed B cell x HMMA2.11TG/O myeloma.

Titer: Use 2 µg of antibody per million cells in flow cytometry and immunofluorescence assays, and 1-10 µg/ml for neutralization assays. Other applications will vary with the requirements of the experimental system.

Special Characteristics: F105 binds to gp120 on the surface of IIIB, SF2, MN, RF, and CC-infected cells. It neutralizes SF2, IIIB, and MN infection at concentrations ranging from 140 ng/ml to 10 µg/ml.

Purified by Protein G chromatography from tissue culture supernatant and quantitated by ELISA.

Endotoxin: Less than 0.5 EU/mL, Lot 150284

*NOTE: Endotoxin has been shown to induce chemokines and other soluble HIV and SIV inhibitory factors in primary cultures of PBMC, monocytes and macrophages (Verani et al., J Exp Med 185:805-816, 1997; J Immunol 168:6388-6396, 2002; Montefiori in preparation). Thus, caution is advised when using this reagent for in vitro studies involving primary cells.

Immunoreactivity is confirmed by ELISA and purity is assessed by SDS-PAGE analysis.

[Click Here for Purity and ELISA Data.](#)

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Recommended Storage: Keep at 4°C for short term storage and -80°C for long term storage. Avoid freeze-thaw cycles as reagent degradation may result.

Contributor: Dr. Marshall Posner and Dr. Lisa Cavacini.

Isotype: IgG₁, kappa.

References: Posner MR, et al. *J Acquired Immune Defic Syndr* **6**:7-14, 1993.
Cavacini LA, et al. *J Acquired Immune Defic Syndr* **6**:353-358, 1993.
Posner MR, et al. *Hybridoma* **6**:611-625, 1987.
Posner MR, et al. *J Immunol* **146**:4325-4332, 1991.

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 gp120 Monoclonal (F105) from Dr. Marshall Posner and Dr. Lisa Cavacini." Also include the references cited above in any publications.

US Patent No. 5215913. Requests from commercial organizations should be directed to Jodi Hecht, Technology Ventures Office, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215. Email: jehecht@bidmc.harvard.edu.

Last Updated June 13, 2016

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.